Palisade Bio Inc Stock Price, News & Analysis

Palisade Bio (NASDAQ: PALI) appointed Sharon Skare as Vice President, Global Head of Clinical Operations on Oct 28, 2025. Ms. Skare brings over 24 years of global clinical development and operations experience across autoimmune, metabolic, gastrointestinal, and fibrotic diseases.

The company is advancing PALI-2108, an orally administered, gut‑restricted prodrug designed to release a PDE4 inhibitor in the terminal ileum and colon. Palisade completed a Phase 1a/1b study with positive data, is conducting a Phase 1b study in fibrostenotic Crohn’s disease, and plans to submit Phase 2 INDs to the FDA in H1 2026. Management expects Skare’s experience in IBD operations and inspection readiness to support clinical and regulatory execution.

Palisade Bio (Nasdaq: PALI) announced first patients dosed in its open-label Phase 1b study of PALI-2108, an ileocolonic-targeted PDE4 inhibitor prodrug for fibrostenotic Crohn’s disease (FSCD), on Oct 20, 2025. The study will enroll ~6–12 patients to evaluate safety, tolerability, PK, PD, tissue pharmacology, and molecular responses over a 14-day dosing period. Topline safety, PK, and PD data are anticipated in Q1 2026. Data plus existing UC program results are planned to support a Phase 2 IND submission in H1 2026.

Palisade Bio (Nasdaq: PALI) announced that the Canadian Intellectual Property Office granted patent No. 3,174,137 for PALI-2108, titled “Gut Microbiota Bioactivated PDE4 Inhibitor Precursors,” providing composition-of-matter protection through May 28, 2041. PALI-2108 is an orally administered, ileocolonic-targeted PDE4 B/D inhibitor designed for fibrostenotic Crohn’s disease (FSCD) and ulcerative colitis (UC). The molecule uses a galactose-derived sugar moiety activated by colonic β-glucuronidase to enable colon-specific distribution with reduced systemic exposure, as shown in a tissue distribution study. Patient dosing in the Phase 1b FSCD study was expected in H2 2025, topline data expected in Q1 2026, and a planned Phase 2 IND submission to FDA is targeted for H1 2026.

Palisade Bio (Nasdaq: PALI) announced on October 9, 2025 that it has cancelled its previously adjourned special meeting of stockholders that had been scheduled to reconvene on October 10, 2025. The meeting was earlier reconvened on September 26, 2025 but adjourned without business due to a lack of quorum.

The company said it still has not received sufficient proxies to constitute a quorum and has withdrawn from stockholder consideration the proposals included in its definitive proxy statement filed with the SEC on August 18, 2025.

Palisade Bio (Nasdaq: PALI) announced closing an upsized public offering on October 2, 2025 that raised approximately $138 million in gross proceeds, including full exercise of the underwriter’s over-allotment option. The offering comprised 197,154,844 shares at a public offering price of $0.70 per share. Proceeds will support the upcoming Phase 2 clinical program for PALI-2108 in ulcerative colitis. Ladenburg Thalmann served as sole book-running manager. SEC registration statements (Form S-1 File Nos. 333-290568 and 333-290644) were effective Sept 30 and Oct 1, 2025.

Palisade Bio (NASDAQ: PALI), a clinical-stage biopharmaceutical company, has announced the pricing of an upsized $120 million underwritten public offering. The offering consists of 171,440,559 shares of common stock priced at $0.70 per share.

The company has granted underwriters a 45-day option to purchase up to an additional 25,714,285 shares at the public offering price. Ladenburg Thalmann & Co. Inc. is serving as the sole book-running manager. The offering is expected to close around October 2, 2025, subject to customary closing conditions.

Palisade Bio (NASDAQ: PALI), a clinical-stage biopharmaceutical company, announced the adjournment of its special meeting of stockholders on September 26, 2025, due to insufficient quorum. The meeting required one-third of outstanding shares present but achieved only 29.68% participation.

The meeting has been rescheduled for October 10, 2025 at 10:00 a.m. Pacific Time in virtual format. Only stockholders of record as of July 28, 2025 are eligible to vote. The company has engaged Mediant Communications Inc. to assist in obtaining the required votes, with a voting deadline of October 9, 2025, at 11:59 p.m. Pacific Time.

Palisade Bio (Nasdaq: PALI), a clinical-stage biopharmaceutical company, announced the adjournment of its special stockholders meeting on September 18, 2025 due to insufficient quorum. The meeting achieved only 28.34% participation of eligible voting shares, falling short of the required one-third quorum threshold.

The meeting has been rescheduled for September 26, 2025 at 10:00 a.m. Pacific Time in virtual format. Only stockholders of record as of July 28, 2025 are eligible to vote. The company has engaged Mediant Communications Inc. to assist in obtaining adequate votes, with a voting deadline of September 25, 2025 at 11:59 p.m. Pacific Time.

Palisade Bio (NASDAQ:PALI) has reported positive Phase 1b clinical data for PALI-2108, its first-in-class, ileocolonic-targeted PDE4 B/D inhibitor for autoimmune and inflammatory diseases. The trial demonstrated 100% clinical response in ulcerative colitis (UC) patients, with 2 out of 5 patients achieving remission after just seven days.

Key findings include no serious adverse events in Phase 1a trials (n=84), and significant improvements in Phase 1b UC cohort (n=5) including a 62.8% mean reduction in modified Mayo score and approximately 70% reduction in fecal calprotectin. The study also showed normalization of 186 genes linked to fibrosis, supporting potential application in fibrostenotic Crohn's disease (FSCD).

The company plans to begin patient dosing for the Phase 1b FSCD study in 2H 2025, with Phase 2 IND submissions anticipated in 1H 2026.